Study type: In vivo/preclinical · Status: Verified against declared source

Thymosin β4 preserves vascular smooth muscle phenotype in atherosclerosis via regulation of low density lipoprotein related protein 1 (LRP1).

International immunopharmacology · 2023

Study scale: Not reported

Abstract only: Open source record

Product or molecular entity relationships

Thymosin Beta-4 (TB500): Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Atherosclerosis is a progressive, degenerative vascular disease and a leading cause of morbidity and mortality.

Limitations and uncertainty

Not reported in the reviewed source.

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.